Arformoterol

This MedLibrary.org supplementary page on Arformoterol is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

Arformoterol
Systematic (IUPAC) name
N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl) propan-2-yl]amino]ethyl] phenyl]formamide
Identifiers
CAS number 67346-49-0
ATC code  ?
PubChem  ?
DrugBank DB01274
Chemical data
Formula C19H24N2O4 
Mol. mass 344.405 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding 52–65%
Metabolism  ?
Half life 26 hours
Excretion  ?
Therapeutic considerations
Licence data

US

Pregnancy cat.

C(US)

Legal status

-only(US)

Routes nebuliser

Arformoterol, also known as arformoterol tartrate (USAN) is a long acting beta-adrenoceptor agonist drug indicated for the treatment of COPD. It is sold by Sepracor, under the tradename Brovana, as a solution to be administered twice daily (morning and evening) by nebulization.[1]

It is the active (R,R)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.

References

External links

Wikipedia content modification information:

  • This page was last modified on 19 July 2008, at 21:18.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Arformoterol".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.